Search results for " Systolic"

showing 7 items of 17 documents

A novel multi-wavelength procedure for blood pressure estimation using opto-physiological sensor at peripheral arteries and capillaries

2018

© 2018 SPIE. In this study, the Carelight multi-wavelength opto-electronic patch sensor (OEPS) was adopted to assess the effectiveness of a new approach for estimating the systolic blood pressure (SBP) through the changes in the morphology of the OEPS signal. Specifically, the SBP was estimated by changing the pressure exerted on an inflatable cuff placed around the left upper arm. Pressure acquisitions were performed both with gold standard (i.e. electronic sphygmomanometer), and Carelight sensor (experimental procedure), on subjects from a multiethnic cohort (aged 28 ± 7). The OEPS sensor was applied together with a manual inflatable cuff, going slightly above the level of the SBP with in…

Materials scienceElectronic sphygmomanometerIdentification errorMulti wavelengthPeripheralInflatableBlood pressuremedicine.arteryCuffSettore ING-IND/12 - Misure Meccaniche E TermichemedicineRadial arteryblood pressure Multi-Wavelength opto-electronic patch sensor (OEPS) photopletismgraphy PPG systolic blood pressure wearable sensorBiomedical engineeringDesign and Quality for Biomedical Technologies XI
researchProduct

Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications

2015

Abstract Systolic and diastolic myocardial dysfunction has been demonstrated to be associated with an activation of the circulating and local renin–angiotensin–aldosterone system (RAAS), and with a subsequent inappropriately increased production of reactive oxygen species (ROS). While, at low concentrations, ROS modulate important physiological functions through changes in cellular signalling and gene expression, overproduction of ROS may adversely alter cardiac mechanics, leading to further worsening of systolic and diastolic function. In addition, vascular endothelial dysfunction due to uncoupling of the nitric oxide synthase, activation of vascular and phagocytic membrane oxidases or mit…

Mitochondrial ROSmedicine.medical_specialtyXanthine OxidasePhosphodiesterase InhibitorsDiastoleAngiotensin-Converting Enzyme InhibitorsReviewmedicine.disease_causeNitric OxideCardiovascular SystemAntioxidantsInternal medicinemedicineHumansEndothelial dysfunctionHeart Failure DiastolicEjection fractionNitratesbusiness.industryDiastolic heart failureNADPH OxidasesStroke VolumeVitaminsHydralazinemedicine.diseaseHydralazineExercise TherapyMitochondriaOxidative StressHeart failureCardiologyDrug Therapy CombinationNitric Oxide SynthaseCardiology and Cardiovascular MedicinebusinessReactive Oxygen SpeciesOxidative stressmedicine.drugHeart Failure Systolic
researchProduct

Feasibility of Ultra-Short-Term Analysis of Heart Rate and Systolic Arterial Pressure Variability at Rest and during Stress via Time-Domain and Entro…

2022

Heart Rate Variability (HRV) and Blood Pressure Variability (BPV) are widely employed tools for characterizing the complex behavior of cardiovascular dynamics. Usually, HRV and BPV analyses are carried out through short-term (ST) measurements, which exploit ~five-minute-long recordings. Recent research efforts are focused on reducing the time series length, assessing whether and to what extent Ultra-Short-Term (UST) analysis is capable of extracting information about cardiovascular variability from very short recordings. In this work, we compare ST and UST measures computed on electrocardiographic R-R intervals and systolic arterial pressure time series obtained at rest and during both post…

electrocardiography (ECG)Short-Term (ST) cardiovascular variabilityBlood PressureHeart Rate Variability (HRV)Settore ING-INF/01 - ElettronicaBiochemistryAtomic and Molecular Physics and OpticsHeart Rate Variability (HRV); Short-Term (ST) cardiovascular variability; Ultra-Short-Term (UST) HRV; electrocardiography (ECG); Systolic Arterial Pressure (SAP); entropy; conditional entropy; complexity; time-series analysisUltra-Short- Term (UST) HRVAnalytical Chemistryconditional entropyElectrocardiographyHeart RateSettore ING-INF/06 - Bioingegneria Elettronica E Informaticatime-series analysisArterial PressureElectrical and Electronic EngineeringentropycomplexitySystolic Arterial Pressure (SAP)InstrumentationSensors; Volume 22; Issue 23; Pages: 9149
researchProduct

Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets

2016

Abstract The European Society of Hypertension recommend the following main rules for treatment of hypertension in elderly and octogenarians: 1) In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 140 mmHg and 150 mmHg. 2) In fit elderly patients less than 80 years old treatment may be considered at SBP ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. 3) In fit individuals older than 80 years with an initial SBP ≥ 160 mmHg it is recommended to reduce SBP to between 150 mmHg and 140 mmHg. 4) In frail elderly patients, it is recommended to base treatment decisions on comorbidity and carefully monitor the effects of tr…

medicine.medical_specialtyBlood Pressure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicinemedicineHumansFrail elderly030212 general & internal medicineIntensive care medicineBlood pressure-lowering treatmentAgedAged 80 and overoctogenarianbusiness.industryGeneral Medicineblood pressure targetmedicine.diseaseComorbidityelderly patientEuropeBlood pressureEuropean Society of HypertensionHypertensionIsolated systolic hypertensionTreatment decision makingCardiology and Cardiovascular MedicinebusinessBlood Pressure
researchProduct

Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish…

2020

Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium sensitivity of cardiomyocytes, acts as a vasodilator due to the opening of potassium channels, and has a cardioprotective effect. Levosimendan is mainly used in the treatment of acute decompensated heart failure (class IIb recommendation according to the European Society of Cardiology guidelines). However, numerous clinical trials indicate the validity of repeated infusions of levosimendan in patients with stable heart failure as a bridge therapy to heart transplantation, and in patients with accompanying right ventricular heart failure and pulmonary hypertension. Due to the complex mechanism of action,…

medicine.medical_specialtyCardiotonic AgentsAcute decompensated heart failureinotropic agentsacute heart failuremedicine.medical_treatment030204 cardiovascular system & hematologylevosimendan03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansinodilatorAdverse effectExpert TestimonySimendanHeart FailureHeart transplantationbusiness.industryHydrazonesLevosimendanmedicine.diseasePulmonary hypertensionCardiac surgeryPyridazinesClinical trialHeart failurechronic advanced systolic heart failureCardiologyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugKardiologia Polska
researchProduct

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial

2020

Funding: This work was supported in part by an unrestricted grant from Vifor Pharma and Proyectos de Investigación de la Sección de Insuficiencia Cardiaca 2017 from Sociedad Española de Cardiología. The mechanisms underlying the beneficial effect of ferric carboxymaltose (FCM) in patients with heart failure (HF) and iron deficiency (ID) have not been completely characterized. The Myocardial-IRON trial was a double-blind, randomized trial that evaluated myocardial iron repletion following FCM vs. placebo in 53 patients with HF and ID. In this post hoc analysis, we evaluated whether treatment with FCM was associated with cardiac magnetic resonance changes in left and right ventricular functio…

medicine.medical_specialtyMyocardial ironHeart failureSystolic function030204 cardiovascular system & hematologyPlaceboFERRIC CARBOXYMALTOSElaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineOriginal Research ArticlesPost-hoc analysismedicineDiseases of the circulatory (Cardiovascular) system030212 general & internal medicineOriginal Research ArticleVentricular systolic functionEjection fractionbusiness.industryIron deficiencymedicine.diseaseFerric carboxymaltoseHeart failureRC666-701CardiologyCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct

Right ventricular function and iron deficiency in acute heart failure

2021

Abstract Aims Iron deficiency (ID) is a frequent finding in patients with chronic and acute heart failure (AHF) along the full spectrum of left ventricular ejection fraction (LVEF). Iron deficiency has been related to ventricular systolic dysfunction, but its role in right ventricular function has not been evaluated. We sought to evaluate whether ID identifies patients with greater right ventricular dysfunction in the setting of AHF. Methods and results We prospectively included 903 patients admitted with AHF. Right systolic function was evaluated by tricuspid annular plane systolic excursion (TAPSE) and the ratio TAPSE/pulmonary artery systolic pressure (TAPSE/PASP). Iron deficiency was de…

medicine.medical_specialtyVentricular Dysfunction Right030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVentricular Function Left03 medical and health sciences0302 clinical medicineLeft ventricle ejection fraction[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineSystoleAgedAged 80 and overHeart FailureIron deficiency.Ejection fractionAnemia Iron-DeficiencybiologyTransferrin saturationbusiness.industryIron deficiencyRight ventricle ejection fractionStroke VolumeGeneral MedicineMiddle AgedPrognosismedicine.disease[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTricuspid annular plane systolic excursionFerritinBlood pressureHeart failureVentricular Function Rightbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusiness
researchProduct